Several factors associated with the generation of inhibitors have been described, among which are the type of genetic mutation, family history, race, major histocompatibility complex (HLA) class I/II, severity of haemophilia, and genetic polymorphisms in interleukin-10 (IL-10) and tissue necrosis factor, as well as factors related to treatment, such as the type of factor concentrate (plasma, recombinant), the frequency of treatment, as well as the age at the initiation of prophylaxis [27,30,33,35,36], as shown in Table 1. This evidence concerns the gene IL10 and hemophilia.